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2002), and after the exclusivity period (February–August
2002) was: $1.89, $1.91, and $1.97 respectively, using an
assumed percentage rebate. Similarly, average estimated
payment per unit (post-rebate) for ﬂuoxetine 20mg 
capsules (generic) in the 2 latter periods was: $1.96 and
$0.79 respectively. Additional payments related to 
cost-savings not realized were estimated to be
$1,772,677. CONCLUSIONS: Regulations that limit
competition within the generic marketplace immediately
following branded patent-expiration may result in lost
opportunities for savings within publicly-ﬁnanced pre-
scription programs.
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OBJECTIVES: The overall purpose of this study was 
to determine West Virginia (WV) physicians’ attitude
toward cost-containment strategies and generic prescrib-
ing, and to assess their level of awareness and receptivity
towards academic detailing. METHODS: The top 2000
physicians by prescribing volume in the WV state employ-
ees health insurance program were surveyed using a 
self-administered mail questionnaire. Physician attitudes
toward popular pharmaceutical cost-control strategies
(formulary, prior-authorization, co-pays, generic and
therapeutic substitution, and incentives for formulary
adherence), generic prescribing, and the potential of 
academic detailing for appropriate and cost-effective
pharmaceutical use was assessed using Likert-type 
7-point scales. Generic prescribing frequency and patient
acceptance/inquiry for generic drugs and the preferred
format of academic detailing visits were also obtained.
RESULTS: A total of 455 (23%) usable responses were
obtained after 2 mailings. On a scale of 1 to 7 (highly
inappropriate to highly appropriate), generic substitu-
tion, increased patient co-pays for branded drugs, and
therapeutic substitution had the highest mean appro-
priateness scores of 5.30 (+1.68), 4.49 (+1.71), and
4.36(+2.01), respectively. All other strategies were 
considered inappropriate with incentives to physicians 
for prescribing from formularies considered the most
inappropriate. Physicians were neutral to mildly positive
toward generic drug prescribing, and reported a mean
proportion of 46% generic prescriptions written and a
78% patient acceptance of generic prescriptions when
written. Physicians were generally aware of academic
detailing and mildly positive about it with 69% of 
surveyed physicians expressing willingness to meet with
academic detailers. A once-a-month frequency of visit and
up to 20 minutes per visit was favored by almost half of
those physicians interested in academic detailing. CON-
CLUSIONS: Overall, WV physicians are less supportive
of cost-control strategies that impose restrictions on their
prescribing and more supportive of strategies that do not
impose on their prescribing. Study results indicate that
WV physicians are receptive to academic detailing.
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ARE SICK PEOPLE LESS RESPONSIVE TO
PRESCRIPTION BENEFIT CHANGES?
Xiao Q, Marks AS, Patel H
Caremark Inc, Northbrook, IL, USA
OBJECTIVES: To estimate the difference in respon-
siveness to drug beneﬁt changes between sick and 
healthy populations under different drug beneﬁt plans.
METHODS: Prescription spending in 2001, demo-
graphic, co-pays and chronic condition information of
107,710 primary participants between ages 18 to 64 was
obtained from Caremark PBM claims system. Existence
of chronic conditions identiﬁed through pharmacy claims
utilization algorithms was used as a proxy for sick people.
A 2-part model was used to estimate the prescription
spending on copay changes. The ﬁrst part used a logistic
regression to estimate the probability of incurring of any
prescription. The second part used an OLS regression 
on log of total spending for the utilizing participants.
RESULTS: Under a 1-Tier copay plan, if the co-pays
increase from $5 to $10, the reduction of total spending
is 6.4% more for sick people than for healthy people.
Under a 2-Tier plan, if the co-pays increase from $5 to
$10 for generic and $10 to $15 for brand, the reduction
of total spending is 10.2% more for sick people than 
for healthy people. Under a 3-Tier plan, if the co-pays
increase from $5 to $10 for generic, $10 to $15 for brand
formulary and $15 to $20 for brand non-formulary, the
reduction of total spending is 10.4% more for sick people
than for healthy people. CONCLUSIONS: Based on the
speciﬁc data set, this research shows that sick people 
are more responsive to drug beneﬁt changes. Since cost-
sharing designs are frequently used to contain total drug
spending, understanding drug beneﬁt designs for hetero-
geneous populations is crucial to achieve the optimal
balance of sponsor savings and participants’ health.
DIABETES
DB1
IMPACT OF PARTICIPANT COST-SHARE ON
COMPLIANCE RATES IN PARTICIPANTS WITH
DIABETES
Moore JM, Marks AS, Kassulke JP, Patel H
Caremark, Inc, Northbrook, IL, USA
OBJECTIVE: To retrospectively assess the impact of par-
ticipant cost-share levels on medication compliance rates
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in participants with diabetes. METHODS: Caremark’s
pharmacy claims database was retrospectively analyzed
to identify participants ﬁlling a prescription for an 
anti-diabetic drug in plans with average participant cost-
sharing of <15% (LOW) or >30% (HIGH) in 2002. Ten
age/gender categories were used to match participants in
the HIGH and LOW study groups. All 2002 anti-diabetic
maintenance drug claims for study participants were 
analyzed. Compliance rates were calculated for each 
therapeutic class as the medication possession ratio. Two
sample t-Tests compared differences in compliance rates
between HIGH and LOW groups. RESULTS: A total 
of 125,963 individual diabetics were identiﬁed (47.7%
HIGH; 46% female; 89% >44yrs). Overall, the mean
medication compliance rates were consistently higher for
the diabetics with low participant cost-share. The mean
medication compliance rate for LOW was 1.00 (95% CI:
1.004, 1.008) and for HIGH was 0.90 (95% CI: 0.903,
0.907; p < .0001). The mean medication compliance rate
for females in LOW was 1.00 (95% CI: 0.999, 1.005)
and in HIGH was 0.89 (95% CI: 0.890, 0.896); for males
in LOW the rate was 1.01 (95% CI: 1.007, 1.012) and
in HIGH was 0.91.(95%CI: 0.912, 0.917; p < .0001).
Mean compliance rates were lower in the high share
group in every age category. The largest difference
occurred for participants 19yrs and younger, where
HIGH had a mean compliance rate of 0.98 (95% CI:
0.95, 1.02), and LOW 1.25 (95% CI: 1.21, 1.28; 
p < .0001). CONCLUSION: This study shows that high
participant cost sharing is associated with decreased 
medication compliance rates for a diabetic population.
While the goal of cost-sharing is to decrease total drug
spending, the amount saved may not offset the effects 
of decreased compliance for maintenance medications in
a diabetic population. More study is needed to better
understand compliance and cost-sharing.
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OBJECTIVES: Until 1995 sulfonylureas were the only
oral diabetes medications available in the United States.
Currently, there are expanded options in diabetes therapy
with ﬁve classes of oral medications. Our objective is to
test whether the newer therapies diffuse more quickly in
higher income areas among an insured population.
METHODS: All prescriptions for oral diabetes medica-
tion issued to patients in metropolitan Baltimore between
1999 and 2001 were selected from CareFirst Inc.’s claims
database. Records were aggregated to the patient level
with indicators for all classes of drugs used. Patients were
divided into those receiving only sulfonylureas and those
receiving at least one of the newer medications. Each
record was linked to census data for median income by
zip code. Linear and logistic regressions were performed
on microdata and data aggregated by zip code. Our null
hypothesis is that income is not associated with use of
newer therapies. We interpret a statistically signiﬁcant
coefﬁcient on income as evidence to reject the null.
RESULTS: The mean proportion of the population
receiving sulfonylureas only declined from 41% to 28%
over the three years. Regression results show a statisti-
cally signiﬁcant negative association between income and
monotherapy. Each $10,000 of income is associated with
a 1% increase in the share of the population recei-
ving newer medications. Controls for age and gender
strengthen this association. Between 1999 and 2001 
the coefﬁcient associating income and likelihood of
monotherapy increased from .003 to .011 (per $10,000).
CONCLUSIONS: Within an insured population, diabet-
ics residing in higher income neighborhoods are more
likely to receive one of the new drug therapies. The level
of this disparity increased over the course of our study. A
subsequent paper will distinguish between co-pay effects
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OBJECTIVES: Maintaining glycemic control is one key
strategy to prevent diabetes-related complications. It is,
however, unclear whether non-adherence to oral antihy-
perglycemic medications contributes to the risk of com-
plications or other outcomes, such as hospitalization. Our
study examines the association between oral medication
non-adherence and subsequent hospitalization among
persons with Type 2 diabetes. METHODS: Administra-
tive claims data (2000 and 2001) from a managed care
organization in the midwestern U.S. were analyzed. The
study included 1270 enrollees, aged 18 and over, with
diabetes who were taking oral antihyperglycemic agents
both years but who did not use insulin. Non-adherence
was deﬁned as a medication possession ratio (MPR)
below 80%. To account for unobserved factors, condi-
tional multivariate logistic regression analyses were 
performed where hospitalization in 2001 was regressed
on non-adherence in 2000, while controlling for prior
hospitalization in 2000, age, gender, and multi-vs.-mono
oral therapy. An interaction term of adherence conver-
sions (from adherent to non-adherent, and vice versa)
between 2000 and 2001 was also analyzed. RESULTS:
Enrollees who were non-adherent to oral antihyper-
glycemic medications in 2000 had greater odds of being
hospitalized in 2001 (OR: 1.80; CI: 1.22–2.67) as com-
pared to those adherent in 2000. Although MPRs within
